

Ingrid Hedenfalk

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5669447/publications.pdf>

Version: 2024-02-01

67
papers

4,769
citations

186265
28
h-index

106344
65
g-index

70
all docs

70
docs citations

70
times ranked

6655
citing authors

#	ARTICLE	IF	CITATIONS
1	Gene-Expression Profiles in Hereditary Breast Cancer. <i>New England Journal of Medicine</i> , 2001, 344, 539-548.	27.0	1,669
2	DNA methylation patterns in hereditary human cancers mimic sporadic tumorigenesis. <i>Human Molecular Genetics</i> , 2001, 10, 3001-3007.	2.9	374
3	An HIF-1 α /VEGF-A Axis in Cytotoxic T Cells Regulates Tumor Progression. <i>Cancer Cell</i> , 2017, 32, 669-683.e5.	16.8	352
4	Characterization of male breast cancer: results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program. <i>Annals of Oncology</i> , 2018, 29, 405-417.	1.2	246
5	Molecular classification of familial non- <i>BRCA1/BRCA2</i> breast cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003, 100, 2532-2537.	7.1	182
6	Clinical and molecular complexity of breast cancer metastases. <i>Seminars in Cancer Biology</i> , 2015, 35, 85-95.	9.6	118
7	Gene expression profiling of primary male breast cancers reveals two unique subgroups and identifies N-acetyltransferase-1 (NAT1) as a novel prognostic biomarker. <i>Breast Cancer Research</i> , 2012, 14, R31.	5.0	100
8	Genome-wide association study identifies a common variant in RAD51B associated with male breast cancer risk. <i>Nature Genetics</i> , 2012, 44, 1182-1184.	21.4	99
9	RNA quality in frozen breast cancer samples and the influence on gene expression analysis - a comparison of three evaluation methods using microcapillary electrophoresis traces. <i>BMC Molecular Biology</i> , 2007, 8, 38.	3.0	89
10	Molecular subtype and tumor characteristics of breast cancer metastases as assessed by gene expression significantly influence patient post-relapse survival. <i>Annals of Oncology</i> , 2015, 26, 81-88.	1.2	75
11	Numb protein expression correlates with a basal-like phenotype and cancer stem cell markers in primary breast cancer. <i>Breast Cancer Research and Treatment</i> , 2010, 122, 315-324.	2.5	70
12	High-resolution genomic profiling of male breast cancer reveals differences hidden behind the similarities with female breast cancer. <i>Breast Cancer Research and Treatment</i> , 2011, 129, 747-760.	2.5	70
13	Claudin α 2 is an independent negative prognostic factor in breast cancer and specifically predicts early liver recurrences. <i>Molecular Oncology</i> , 2014, 8, 119-128.	4.6	61
14	Statin-induced anti-proliferative effects via cyclin D1 and p27 in a window-of-opportunity breast cancer trial. <i>Journal of Translational Medicine</i> , 2015, 13, 133.	4.4	53
15	Characterizing steroid hormone receptor chromatin binding landscapes in male and female breast cancer. <i>Nature Communications</i> , 2018, 9, 482.	12.8	50
16	The Landscape of Candidate Driver Genes Differs between Male and Female Breast Cancer. <i>PLoS ONE</i> , 2013, 8, e78299.	2.5	46
17	ERK1/2 inhibition increases antiestrogen treatment efficacy by interfering with hypoxia-induced downregulation of ER α : a combination therapy potentially targeting hypoxic and dormant tumor cells. <i>Oncogene</i> , 2005, 24, 6835-6841.	5.9	45
18	Co-targeting of the PI3K pathway improves the response of BRCA1 deficient breast cancer cells to PARP1 inhibition. <i>Cancer Letters</i> , 2012, 319, 232-241.	7.2	45

#	ARTICLE	IF	CITATIONS
19	Molecular subtyping of male breast cancer using alternative definitions and its prognostic impact. <i>Acta Oncologica</i> , 2013, 52, 102-109.	1.8	45
20	Afadin cooperates with Claudin-2 to promote breast cancer metastasis. <i>Genes and Development</i> , 2019, 33, 180-193.	5.9	45
21	Global Transcriptional Changes Following Statin Treatment in Breast Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 3402-3411.	7.0	44
22	Characterization of a Novel Breast Carcinoma Xenograft and Cell Line Derived from a BRCA1 Germ-Line Mutation Carrier. <i>Laboratory Investigation</i> , 2003, 83, 387-396.	3.7	43
23	PD-1/PD-L1 expression and tumor-infiltrating lymphocytes are prognostically favorable in advanced high-grade serous ovarian carcinoma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2020, 477, 83-91.	2.8	41
24	Transcriptional Profiling of Breast Cancer Metastases Identifies Liver Metastasis-Associated Selective Genes Associated with Adverse Outcome in Luminal A Primary Breast Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 146-157.	7.0	38
25	Similarities and differences in the characteristics and primary treatment of breast cancer in men and women – a population based study (Sweden). <i>Acta Oncologica</i> , 2011, 50, 1083-1088.	1.8	34
26	Molecular profiling of male breast cancer – Lost in translation?. <i>International Journal of Biochemistry and Cell Biology</i> , 2014, 53, 526-535.	2.8	34
27	Regulatory T lymphocyte infiltration in metastatic breast cancer – an independent prognostic factor that changes with tumor progression. <i>Breast Cancer Research</i> , 2021, 23, 27.	5.0	33
28	Increased gene copy number of <i>KIT</i> and <i>VEGFR2</i> at 4q12 in primary breast cancer is related to an aggressive phenotype and impaired prognosis. <i>Genes Chromosomes and Cancer</i> , 2012, 51, 375-383.	2.8	31
29	Claudin-4 Expression is Associated With Survival in Ovarian Cancer But Not With Chemotherapy Response. <i>International Journal of Gynecological Pathology</i> , 2018, 37, 101-109.	1.4	31
30	Oncogenic translation directs spliceosome dynamics revealing an integral role for SF3A3 in breast cancer. <i>Molecular Cell</i> , 2021, 81, 1453-1468.e12.	9.7	31
31	Contrasting breast cancer molecular subtypes across serial tumor progression stages: biological and prognostic implications. <i>Oncotarget</i> , 2015, 6, 33306-33318.	1.8	31
32	Tiling array-CGH for the assessment of genomic similarities among synchronous unilateral and bilateral invasive breast cancer tumor pairs. <i>BMC Clinical Pathology</i> , 2008, 8, 6.	1.8	28
33	Laser capture microdissection (LCM) and whole genome amplification (WGA) of DNA from normal breast tissue – optimization for genome wide array analyses. <i>BMC Research Notes</i> , 2011, 4, 69.	1.4	28
34	High proliferation is associated with inferior outcome in male breast cancer patients. <i>Modern Pathology</i> , 2013, 26, 87-94.	5.5	27
35	Sex Steroid Hormone Receptor Expression Affects Ovarian Cancer Survival. <i>Translational Oncology</i> , 2015, 8, 424-433.	3.7	27
36	Assessment of early response biomarkers in relation to long-term survival in patients with HER2-negative breast cancer receiving neoadjuvant chemotherapy plus bevacizumab: Results from the Phase II PROMIX trial. <i>International Journal of Cancer</i> , 2018, 142, 618-628.	5.1	27

#	ARTICLE	IF	CITATIONS
37	Genomic alterations in histopathologically normal breast tissue from BRCA1 mutation carriers may be caused by BRCA1 haploinsufficiency. <i>Genes Chromosomes and Cancer</i> , 2010, 49, 78-90.	2.8	26
38	Cyclin E Overexpression Obstructs Infiltrative Behavior in Breast Cancer: A Novel Role Reflected in the Growth Pattern of Medullary Breast Cancers. <i>Cancer Research</i> , 2005, 65, 9727-9734.	0.9	25
39	Nuclear HIF1A expression is strongly prognostic in sporadic but not familial male breast cancer. <i>Modern Pathology</i> , 2014, 27, 1223-1230.	5.5	23
40	Microarrays in breast cancer research and clinical practice – the future lies ahead. <i>Endocrine-Related Cancer</i> , 2006, 13, 1017-1031.	3.1	22
41	Extracellular lipid loading augments hypoxic paracrine signaling and promotes glioma angiogenesis and macrophage infiltration. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 241.	8.6	21
42	Involvement of Chromatin Remodeling Genes and the Rho GTPases RhoB and CDC42 in Ovarian Clear Cell Carcinoma. <i>Frontiers in Oncology</i> , 2017, 7, 109.	2.8	20
43	Abstract S6-05: Characterization of male breast cancer: First results of the EORTC10085/TBCRC/BIG/NABCC International Male BC Program. , 2015, , .		20
44	Gene Expression Profiling of Hereditary and Sporadic Ovarian Cancers Reveals Unique BRCA1 and BRCA2 Signatures. <i>Journal of the National Cancer Institute</i> , 2002, 94, 960-961.	6.3	19
45	Distinct mechanisms of resistance to fulvestrant treatment dictate level of ER independence and selective response to CDK inhibitors in metastatic breast cancer. <i>Breast Cancer Research</i> , 2021, 23, 26.	5.0	19
46	Dynamic evaluation of the immune infiltrate and immune function genes as predictive markers for neoadjuvant chemotherapy in hormone receptor positive, HER2 negative breast cancer. <i>OncImmunity</i> , 2018, 7, e1466017.	4.6	18
47	Molecular Subtyping of Serous Ovarian Tumors Reveals Multiple Connections to Intrinsic Breast Cancer Subtypes. <i>PLoS ONE</i> , 2014, 9, e107643.	2.5	17
48	A Case-Matched Gender Comparison Transcriptomic Screen Identifies eIF4E and eIF5 as Potential Prognostic Markers in Male Breast Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 2575-2583.	7.0	16
49	A multiplex biomarker assay improves the diagnostic performance of HE4 and CA125 in ovarian tumor patients. <i>PLoS ONE</i> , 2020, 15, e0240418.	2.5	15
50	Genome methylation patterns in male breast cancer – Identification of an epitype with hypermethylation of polycomb target genes. <i>Molecular Oncology</i> , 2015, 9, 1565-1579.	4.6	14
51	High-throughput genomic technology in research and clinical management of breast cancer. Molecular signatures of progression from benign epithelium to metastatic breast cancer. <i>Breast Cancer Research</i> , 2006, 8, 213.	5.0	13
52	Combination of the proliferation marker cyclin A, histological grade, and estrogen receptor status in a new variable with high prognostic impact in breast cancer. <i>Breast Cancer Research and Treatment</i> , 2012, 131, 33-40.	2.5	13
53	The combination of Ki67, histological grade and estrogen receptor status identifies a low-risk group among 1,854 chemo-naïve women with NO/N1 primary breast cancer. <i>SpringerPlus</i> , 2013, 2, 111.	1.2	12
54	Common Susceptibility Loci for Male Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2021, 113, 453-461.	6.3	12

#	ARTICLE	IF	CITATIONS
55	Homologous Recombination Repair Mechanisms in Serous Endometrial Cancer. <i>Cancers</i> , 2021, 13, 254.	3.7	12
56	Detecting TP53 mutations in diagnostic and archival liquid-based Pap samples from ovarian cancer patients using an ultra-sensitive ddPCR method. <i>Scientific Reports</i> , 2019, 9, 15506.	3.3	10
57	Crizotinib and PARP inhibitors act synergistically by triggering apoptosis in high-grade serous ovarian cancer. <i>Oncotarget</i> , 2019, 10, 6981-6996.	1.8	9
58	Ghrelin expression is associated with a favorable outcome in male breast cancer. <i>Scientific Reports</i> , 2018, 8, 13586.	3.3	8
59	Requirement of Apoptotic Protease-Activating Factor-1 for Bortezomib-Induced Apoptosis but Not for Fas-Mediated Apoptosis in Human Leukemic Cells. <i>Molecular Pharmacology</i> , 2013, 83, 245-255.	2.3	7
60	SOX2 is a promising predictor of relapse and death in advanced stage high-grade serous ovarian cancer patients with residual disease after debulking surgery. <i>Molecular and Cellular Oncology</i> , 2020, 7, 1805094.	0.7	7
61	MET Expression and Cancer Stem Cell Networks Impact Outcome in High-Grade Serous Ovarian Cancer. <i>Genes</i> , 2021, 12, 742.	2.4	6
62	Gene expression modules in primary breast cancers as risk factors for organotropic patterns of first metastatic spread: a case control study. <i>Breast Cancer Research</i> , 2017, 19, 113.	5.0	5
63	Protein Signature Predicts Response to Neoadjuvant Treatment With Chemotherapy and Bevacizumab in HER2-Negative Breast Cancers. <i>JCO Precision Oncology</i> , 2021, 5, 286-306.	3.0	5
64	High density of stroma-localized CD11c-positive macrophages is associated with longer overall survival in high-grade serous ovarian cancer. <i>Gynecologic Oncology</i> , 2020, 159, 860-868.	1.4	4
65	Evaluation of multiple transcriptomic gene risk signatures in male breast cancer. <i>Npj Breast Cancer</i> , 2021, 7, 98.	5.2	4
66	Simvastatin is a potential candidate drug in ovarian clear cell carcinomas. <i>Oncotarget</i> , 2020, 11, 3660-3674.	1.8	4
67	Abstract P2-08-11: How reliable are biomarkers assessed on a core needle biopsy? A study of paired core needle biopsies and surgical specimens in early breast cancer. <i>Cancer Research</i> , 2022, 82, P2-08-11-P2-08-11.	0.9	0